FDA Pushes for New Buprenorphine Labeling 🔗 Access full article via Medscape NeurologyThe FDA urges manufacturers to revise labeling of transmucosal buprenorphine products to ease access to higher doses because of the rise of high-potency opioids like fentanyl. Medscape Medical News Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
